Artificial intelligence continues to demonstrate high diagnostic accuracy in tuberculosis radiography and genomic drug-resistance prediction, but implementation barriers remain a central limiter. The review emphasizes the gap between algorithmic performance and operational readiness in real clinical workflows. Separately, research on automated image-based reading of tuberculin skin tests found insufficient evidence to support routine implementation, signaling caution in scaling AI screening without stronger clinical validation. For biotech leaders building diagnostics, the message is clear: proof of accuracy must be paired with evidence on calibration, generalization, workflow integration, and demonstrated clinical impact—especially in screening settings.
Get the Daily Brief